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Abstract
Background: The role of long non-coding RNAs has been extensively appreciated in the contexts of cancer. Interferon
γ-antisense RNA1 (IFNG-AS1) is an lncRNA located near to IFN-γ-encoding (IFNG) gene and regulates expression of IFNG
in Th1 cells.
Methods: In the present study, we evaluated expression of IFNG and IFNG-AS1 in 108 breast samples including tumoral
tissues and their adjacent non-cancerous tissues (ANCTs) using real-time PCR. IFNG-AS1 was significantly upregulated in
tumoral tissues compared with ANCTs (expression ratio = 2.23, P = 0.03).
Results: Although the expression of IFNG was higher in tumoral tissues compared with ANCTs (relative expression = 1.89),
it did not reach the level of significance (P = 0.07). IFNG expression was significantly higher in HER2-negative tumoral
tissues compared with HER2-positive ones (P = 0.01) and in grade 1 samples compared with grade 2 ones (P = 0.03).
No other significant difference was found in expressions of genes between other groups.
Conclusion: Significant strong correlations were detected between expression of IFNG and IFNG-AS1 in both tumoral
tissues and ANCTs. The present study provides evidences for participation of IFNG and IFNG-AS1 in the pathogenesis of
breast cancer and warrants future studies to elaborate the underlying mechanism.
Keywords: IFNG, IFNG-AS1, Breast cancer
Background
Long non-coding RNAs (lncRNAs) are increasingly ac-
knowledged as principal regulators of gene expression in
the contexts of both cancer [1] and immunological dis-
orders [2]. Considering the prominent role of immune
system in control of carcinogenesis process, lncRNAs
with regulatory roles on both immune cells and cancer
cells are of particular value as tumor biomarkers or
therapeutic targets. Interferon γ-antisense RNA1 (IFN-
G-AS1) is located near to IFN-γ-encoding (IFNG) gene.
This lncRNA is regarded as a fundamental checkpoint
that participates in IFNG expression in Th1 cells [3].
Targeting immune checkpoint molecules has been sug-
gested as a new approach in cancer treatment. The spe-
cific pattern of expression of non-coding RNAs in tumoral
tissues and their participation in initial phases of modula-
tion of immune responses have potentiate them as novel
candidates for changing the tumor microenvironment [4].
As IFN-based strategies along with immune checkpoint
inhibitors are putative therapeutic options for malignan-
cies [4], therapeutic modulation of IFNG-AS1 expression
would exert beneficial effects in cancer patients from di-
verse aspects. Elevated expression of IFNG-AS1 lncRNA
has been reported in Hashimoto’s thyroiditis (HT) patients
in correlation with the proportion of circulating Th1 cells
and IFNG gene expression [5]. The role of IFN-γ has been
documented in both breast cancer pathogenesis and pa-
tients’ response to treatments. IFN-γ has been initially rec-
ognized for its role in antitumor host immunity which is
exerted through induction of Th1 polarization and activa-
tion of both cytotoxic T cells (CTLs) and dendritic cells.
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favor of tumor progression which has been documented
by the observed negative effect of IFN-γ treatment on pa-
tient survival in some clinical trials. The underlying mech-
anism for such negative effect might be irresponsiveness
to IFN-γ, downregulation of the MHC complex, or over-
expression of other genes such as programmed cell death
1 ligand 1 (PD-L1) [6]. On the other hand, overexpression
of IFN/STAT1-related genes has been suggested as prog-
nostic markers of response to chemotherapy in estrogen re-
ceptor (ER) negative breast cancers [7]. More importantly,
IFN-γ treatment in conjunction with anti-erbB2/neu mAb
has significantly suppressed tumor growth in animal
models [8]. In spite of several efforts to evaluate the effi-
ciency of IFN-γ treatment in breast cancer, data regarding
expression of IFNG gene in breast cancer tissues is scarce.
In the present study, we assessed expression of IFNG
gene and its natural occurring antisense RNA in 108
breast samples including tumoral tissues and their adja-
cent non-cancerous tissues (ANCTs) using real-time
PCR in association with patients clinicopathological
characteristics.
Methods
Patients
The current study enrolled 54 breast cancer patients. All
patients had invasive ductal carcinoma of breast based
on the histological examination. All of them have been
recently diagnosed as having breast cancer and had no
previous chemo/radiotherapy. The patients were admit-
ted to Sina and Farmanieh hospitals over the years
2016–2017. The research protocol was approved by the
ethical committee of Shahid Beheshti University of Medical
Sciences (IR.SBMU.RETECH.REC.1397.403). All methods
were performed in accordance with the relevant guidelines
and regulations. Informed written consent was obtained
from all patients. Tumoral tissues and ANCTs (0.5 cm ×
0.5 cm) were excised from all patients during surgery,
transferred in liquid nitrogen to the genetic laboratory
of Shahid Beheshti University of Medical Sciences. Tis-
sue samples were assessed by pathologists to endorse
the diagnosis.
Expression analysis
Relative expressions of IFNG and IFNG-AS1 genes were
assessed in tumoral tissues and paired ANCTs in the
rotor gene 6000 Corbett Real-Time PCR System. Total
RNA was extracted from tissue samples using TRIzol™
Reagent (Invitrogen, Carlsbad, CA, USA), and cDNA
was synthesized by using RevertAid First Strand cDNA
Synthesis Kit (TaKaRa, Japan). Al samples were treated
with DNAse I to remove DNA contamination. SYBR
Table 1 The nucleotide sequences of primers used for
expression analysis
Gene name Primer sequence Primer
length
Product
length
B2M F: AGATGAGTATGCCTGCCGTG 20 104
R: CGGCATCTTCAAACCTCCA 19
IFNG F: GGCAAGGCTATGTGATTACAAGG 23 96
R:CATCAAGTGAAATAAACACACAACCC 26
IFNG-AS1 F: AGGAAGCTGGGTAATTGAATGC 22 94
R: CTTAGGAGGAGAATTTTGGGAGAG 24
Fig. 1 The relative expression of IFNG and IFNG-AS1 in tumoral tissues (n = 54) and ANCTs (n = 54) as presented by –delta CT values (CT
housekeeping - CT target gene) in each set of samples
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Green RT-PCR Master Mix (TaKaRa, Japan) was used
for expression analysis of genes. Expressions of genes
were normalized to expression of Beta 2 microglobulin
(B2M). The nucleotide sequences of primers are shown
in Table 1. All experiments were performed in duplicate.
Statistical analysis
Student’s paired t test was used for analysis of differ-
ences in gene expression between paired samples. The
association between clinicopathological data and tran-
script levels of each gene was assessed using chi-
square test. Tukey’s honest significance test was used
to assess the difference between mean values of tran-
script levels between different groups. The efficiency-
corrected calculation model was used for assessment
of fold changes of expression levels in tumoral tissues
vs. ANCTs. The pairwise correlation between relative
transcripts levels of IFNG and IFNG-AS1 genes was
calculated using the regression model. For all statis-
tical tests, the level of significance was set at P < 0.05.
The receiver operating characteristic (ROC) curve was
designed to assess the properness of gene expression
levels for differentiating tumoral vs. ANCTs. The You-
den index (j) was used to escalate the difference between
sensitivity (true-positive rate) and 1 – specificity (false-
positive rate).
Results
Elevated levels of IFNG and IFNG-AS1 can be used to
identify breast cancer
IFNG-AS1 was significantly upregulated in tumoral tis-
sues compared with ANCTs (expression ratio = 2.23,
P = 0.03). Although the expression of IFNG was higher in
Fig. 2 Correlation between relative expressions of IFNG and IFNG-AS1 in tumoral (a) and ANCTs (b)
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tumoral tissues compared with ANCTs (relative expression
= 1.89), it did not reach the level of significance (P = 0.07).
Figure 1 shows the –delta CT values (CT housekeeping -
CT target gene) in tumoral tissues and ANCTs.
Assessment of correlation between expressions of
IFNG and IFNG-AS1 genes revealed strong correlations
between their expressions in both tumoral tissues and
ANCTs (Fig. 2a, b).
IFNG expression status is associated with clinical features
of breast cancer
Table 2 shows the summary of demographic and clinico-
pathological data of study participants which have been
gathered from questionnaires and patients’ medical records.
We compared expression level of IFNG and IFNG-AS1
in each tumoral tissue vs. its paired ANCT and classified
patients based on these values to upregulation and
downregulation groups. INFG and IFNG-AS1 were up-
regulated in tumoral tissues obtained from 35/54 (64%)
and 37/54 (68%) of patients, respectively. Subsequently,
we evaluated associations between clinicopathological
data and relative expressions of IFNG and IFNG-AS1
genes. No significant associations were found between
patients’ clinicopathological data and fold changes of ex-
pression of these genes in tumoral tissues compared
with ANCTs. Table 3 shows the results of association
analysis between relative expressions of genes in tumoral
tissues compared with ANCTs and patients’ clinicopath-
ological data.
Next, we compared relative expression of each gene
in tumoral samples between clinicopathological-based
groups (Table 4). IFNG expression was significantly
higher in HER2-negative tumoral tissues compared
with HER2-positive ones (P = 0.01) and in grade 1
samples compared with grade 2 ones (P = 0.03). No
other significant difference was found in expressions
of genes between other groups.
Assessment of the diagnostic value of IFNG and IFNG-AS1
in breast cancer
Based on the results of ROC curve analysis IFNG and
IFNG-AS1 expressions had 83.3% specificity and 85.2%
sensitivity for identification of disease status, respectively.
The results of ROC curve analysis are shown in Fig. 3 and
Table 5.
Discussion
In the present study, we evaluated transcript levels of
IFNG and IFNG-AS1 in breast cancer tissues and their
paired ANCTs and found significant upregulation of
IFNG-AS1 in tumoral tissues. IFNG-AS1 has been previ-
ously shown to regulate the expression of IFNG at both
transcriptional and translational level in human CD4+
T cells [5]. Besides, strong positive correlations have
been detected between the transcript levels of these
two genes in thyroid tissues from HT patients [5]. Our
data revealed the similar pattern of correlation between
transcript levels of these genes in both tumoral tissues
and ANCTs.
We could not find significant difference in expression
of IFNG between tumoral tissues and ANCTs. García-
Tuñón et al. have previously evaluated expression of
Table 2 General demographic data of study participants
Variables Values
Age (years) (mean ± SD) 51.79 ± 13.54 (29–81)
Menarche age (years) (mean ± SD) 13 ± 1.65 (10–18)
Menopause age (years) (mean ± SD) 44.91 ± 14.91 (38–60)
First pregnancy age (years) (mean ± SD) 18.04 ± 8.36 (14–32)
Breast feeding duration (months) (mean ± SD) 41.62 ± 34.1 (3–120)
Positive family history for cancer (%) 17%
Cancer stage (%)
I 30.8
II 28.8
III 30.8
IV 9.6
Overall grade (%)
I 17
II 49
III 34
Mitotic rate (%)
I 45.2
II 42.9
III 11.9
Tumor size (%)
< 2 cm 32
≥ 2 cm, < 5 cm 66
≥ 5 cm 2
Estrogen receptor (%)
Positive 87.8
Negative 12.2
Progesterone receptor (%)
Positive 77.1
Negative 22.9
Her2/neu expression (%)
Positive 25
Negative 75
Ki67 expression (%)
Positive 100
Negative 0
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IFNG in fibrocystic lesions, in situ tumors, and infiltrat-
ing tumors of breast and found higher expression of
IFNG in in situ carcinoma than in benign and infiltrat-
ing tumors. They proposed IFNG as a prospective thera-
peutic modality in breast cancer [9]. In line with their
observation, we found higher levels of IFNG in grade 1
samples compared with grade 2 ones. It is possible that
tumor cells downregulate expression of IFNG as a mech-
anism for escaping from immune surveillance. We also
detected higher IFNG expression in HER2-negative
tumoral tissues compared with HER2-positive ones. IFN-γ
has been previously shown to downregulate expression of
HER2 in prostate cancer cells [10]. The existence of simi-
lar mechanism in breast cancer cells needs to be assessed.
However, the direct effect of IFN-γ on HER2-positive
breast cancer cells as reported by Nagai et al. [11] sup-
ports a similar function in the context of breast cancer.
Consistent with García-Tuñón et al. [9], we did not
find any association between IFNG expression and ER/
PR status. Mostafa et al. have shown an ERα inhibitory
Table 3 The results of association analysis between relative expressions of genes in tumoral tissues compared with ANCTs and
patients’ clinicopathological data (up/downregulation of genes was defined based on relative expression of each gene in tumoral
tissue compared with the paired ANCT)
IFNG upregulation IFNG downregulation P value IFNG-AS1 upregulation IFNG-AS1 downregulation P value
Age 0.63 0.5
< 40 8 (67.6%) 3 (27.3%) 9 (81.8%) 2 (18.2%)
40–50 10 (58.2%) 7 (41.2%) 11 (64.7%) 6 (35.3%)
51–60 10 (76.9%) 3 (23.1%) 10 (76.9%) 3 (23.1%)
61–70 5 (62.5%) 3 (37.5%) 5 (62.5%) 3 (37.5%)
> 71 2 (40%) 3 (60%) 2 (40%) 3 (60%)
Stage 0.95 0.25
1 9 (56.3%) 7 (43.7%) 10 (62.5%) 6 (37.5%)
2 10 (66.7%) 5 (33.3%) 9 (60%) 6 (40%)
3 11 (68.8%) 5 (31.2%) 14 (87.5%) 2 (12.5%)
4 4 (80%) 1 (20%) 3 (20%) 2 (80%)
Histological grade 0.87 0.91
1 5 (62.5%) 3 (37.5%) 6 (75%) 2 (25%)
2 16 (69.6%) 7 (30.4%) 15 (62.5%) 8 (34.8%)
3 10 (62.5%) 6 (37.5%) 12 (75%) 4 (25%)
Mitotic rate 0.9 0.64
1 13 (68.4%) 6 (31.6%) 14 (73.7%) 5 (26.3%)
2 11 (61.1%) 7 (38.9%) 11 (61.1%) 7 (38.9%)
3 3 (60%) 2 (40%) 4 (80%) 1 (20%)
Tumor size 0.7 0.67
< 2 9 (56.3%) 7 (43.7%) 12 (75%) 4 (25%)
2–5 22 (66.7%) 11 (33.3%) 21 (63.6%) 12 (36.4%)
> 5 1 (100%) 0 (0%) 1 (100%) 0 (0%)
ER status 0.08 0.65
Positive 26 (60.5%) 17 (39.5%) 29 (67.4%) 14 (32.6%)
Negative 6 (100%) 0 (0%) 5 (16.7%) 1 (83.3%)
PR status 0.07 0.46
Positive 22 (59.5%) 15 (40.5%) 25 (67.6%) 12 (32.4%)
Negative 10 (90.9%) 1 (9.1%) 9 (81.8%) 2 (18.2%)
HER2 status 0.48 0.27
Positive 7 (58.3%) 5 (41.7%) 7 (58.3%) 5 (41.7%)
Negative 25 (69.4%) 11 (30.6%) 27 (75%) 9 (25%)
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effect on IFN-γ signaling which results in immune es-
cape in ERα-positive breast cancer cells [12]. However,
such inhibitory effects are not necessarily exerted on ex-
pression of IFNG itself. Future studies are needed to as-
sess the effect of estradiol or its receptor on IFNG
expression.
We observed higher levels of IFNG-AS1 in breast
cancer tissues compared with ANCTs. This finding
might be either the cause or the consequence of the
tumorigenesis process. Future functional studies are
needed to elaborate the consequence of its overex-
pression in breast tissues. As previous studies have
linked its overexpression with autoimmune condi-
tions, it is possible that such overexpression is a com-
pensatory mechanism to conquer immune evasion in
tumor microenvironment. Critchley-Thorne et al. have
evaluated the effectiveness of IFNG in peripheral blood
lymphocytes from breast cancer patients and detected
diminished IFN-γ-induced signaling in B cells of these
patients in spite of normal signaling in T cells or nat-
ural killer cells [13]. Noticeably, no difference has been
found within stages II, III, and IV breast cancer patients
in this regard [13] which is in accordance with our
finding regarding similar expression of the IFNG gene
Table 4 Comparison of expression levels of IFNG and IFNG-AS1 genes in tumoral tissue of breast cancer patients between
clinicopathological-based categories (mean and SD values of (E^CTB2M/E^CTtarget gene) are presented)
IFNG P value IFNG-AS1 P value
Age
Pre-menopause vs. post-menopause 0.02 (0.04) vs. 0.03 (0.04) 0.59 0.01 (0.01) vs. 0.01 (0.02) 0.78
ER status
ER(+) vs. ER(−) 0.03 (0.05) vs. 0.02 (0.01) 0.66 0.01 (0.02) vs. 0.01 (0.01) 0.97
PR status
PR(+) vs. PR(−) 0.03 (0.05) vs. 0.02 (0.02) 0.74 0.01 (0.02) vs. 0.01 (0.01) 0.92
HER2 status
HER2(+) vs. HER2(−) 0.009 (0.01) vs. 0.03 (0.05) 0.01 0.01 (0.01) vs. 0.01 (0.02) 0.57
Tumor grade
Grade 1 vs. 2 0.06 (0.08) vs. 0.01 (0.03) 0.03 0.02 (0.02) vs. 0.01 (0.02) 0.73
Grade 1 vs. 3 0.06 (0.08) vs. 0.02 (0.02) 0.1 0.02 (0.02) vs. 0.01 (0.01) 0.69
Grade 2 vs. 3 0.01 (0.03) vs. 0.02 (0.02) 0.89 0.01 (0.02) vs. 0.01 (0.01) 0.99
Fig. 3 ROC curve for prediction of disease status based on the expression levels of IFNG and IFNG-AS1
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in histopathological-based groups. Consequently, there
is a cell type-dependent regulatory mechanism for IFN
function. So, future studies are needed to elaborate
such mechanism in the epithelial tissues obtained from
breast tumors to find whether these functional re-
sponses are impaired in the cancer tissue. Moreover,
the significance of local expression of IFNG and IFN-
G-AS1 in response to systemic IFN-γ therapy of breast
cancer patients must be investigated in imminent
researches.
Conclusion
Apart from functional consequences of dysregulation of
IFNG-AS1 in breast tumor tissues, transcript levels of
this gene might be used for diagnosis purposes in the
panels of putative biomarkers comprising both coding
and non-coding genes. However, based on the results of
ROC curve analysis, none of the assessed genes in the
present study fulfill the requirements as an individual
biomarker as the AUC values of both genes and their
combinations were between 0.6 and 0.7 which means
the poor accuracy of a diagnostic test.
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